Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV 10% Efficacy and Safety in Multifocal Motor Neuropathy
NCT00666263Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2008
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in multifocal motor neuropathy (MMN), sponsored by Takeda. Started Aug 2008; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT00666263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666263.